NewsBenzinga아크리본 테라퓨틱스, 제38회 EORTC-NCI-AACR 분자 표적 및 암 치료제 심포지엄에서 ACR-2316의 현재 1/2상 임상시험 용량 증량 데이터 발표 예정 아크리본 테라퓨틱스, 제38회 EORTC-NCI-AACR 분자 표적 및 암 치료제 심포지엄에서 ACR-2316의 현재 1/2상 임상시험 용량 증량 데이터 발표 예정 Benzinga 2026.10.29 12:04 (GMT+0) Open on Benzinga Other news Leerink Partners Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $35 What's Going on With AST SpaceMobile Stock on Monday? Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years Stock of the Day: Is Pepsi About to Break Out? Intel Extends Slide as Nvidia Trims Stake 25%, Shareholder Suit Adds Pressure HC Wainwright & Co. Maintains Buy on Soluna Holdings, Lowers Price Target to $3
Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years